# Seizure and COVID-19


ศ.นพ. คณิตพงษ์ ปราบพาล.


- Pathophysiology
- Neurological involvement
- Patients without epilepsy
  - Seizure
  - EEG
  - Treatment
  - Epilepsy
- Patients with epilepsy


- Pathophysiology
- Neurological involvement
- Patients without epilepsy
  - Seizure
  - EEG
  - Treatment
  - Epilepsy
- Patients with epilepsy

#### Pathophysiology










ID-19)

om/video/x7samry

# Pathophysiology Direct effect

- Transneuronal: neuroinvasio, Neurotrophism
  - Acute encephalitis, SARS-CoV related deaths: HCoV strain 229E,, HCoV stain OC43,
  - Anosmia: SARS-CoV-2
- Blood brain barrier compromised
- Hematogenous route






https://psychscenehub.com/wp-content/uploads/2020/05/Coronavirus-entry-through-nose-olfactory-ciliated-and-goblet-cells.jpg

### Pathophysiology

indirect effect Cytokines strome Immun system Endothelial damage activation Organ failure COVID-19 Metabolic disturbance

Seizure

#### Encephalitis



https://pubs.rsna.org/cms/10.1148/radiol.2020201187/asset/images/medium/radiol.2020201187.fig2.gif

Activation of pro-coagulant factors

Coagulopathies & Thrombus formation



https://pbs.twimg.com/media/D8yIG-HXoAEnHy3.jpg

- Pathophysiology
- Neurological involvement
- Patients without epilepsy
  - Seizure
  - EEG
  - Treatment
  - Epilepsy
- Patients with epilepsy

## Neurological involvement

Asadi-Pooya AA et al. J Neurol Sci 2020 inpress

Author/year	Methods			
	Study design/populations	Numbers	Country	Neurological maifectration
Mao/2020	Retrospective/ admitted patients	214	Wuhan/China	CNS manifestation (25%): headache (13%), dizziness (13%), impaired consciousness (8%) acute cerebrovascular problem (3%), ataxia (0.5%), seizure (0.5%)
Li/2020	Retrospective/ admitted patients	221	Wuhan/China	IS (5%), CVST (0.5%), cerebral haemorrhage (0.5%)
Huang/2020	Prospective/ admitted	41	Wuhan/China	Headache (8%)
Yang/2020	Retrospective/ critical ill adult patients	52	Wuhan/China	Headache (6%)
Wang/2020	Retrospective/ admitted	138	Wuhan/China	Dizziness (9%), Headache (7%)
Chen/2020	Retrospective/ admitted	99	Wuhan/China	Confusion (9%), headache (8%)

Mao T et al. https://www.medrxiv.org/content/10.1101/2020.02.22.20026500v1/. Li Y et al. https://papers.ssrn.com/sol3/ papers.cfm?abstract\_id=3550025/,

Huanf C et al. Lancet 2000: 395; 497-506

Yang X, C et al. Lancet Res. Med 2000 inpress

Wang D et al. JAMA 2020 inpress

Chen N et al. Lancet 2000: 395; 507-513

#### **Original Investigation**

FREE

April 10, 2020


#### Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China

Ling Mao<sup>1</sup>; Huijuan Jin<sup>1</sup>; Mengdie Wang<sup>1</sup>; et al

Author Affiliations | Article Information

JAMA Neurol. 2020;77(6):683-690. doi:10.1001/jamaneurol.2020.1127

No CSF study, no EEG, no clear definitions



## Neurological involvement

Asadi-Pooya AA et al. J Neurol Sci 2020 inpress

Author/year	Methods			
	Study design/populations	Numbers	Country	Neurological maifectration
Mao/2020	Retrospective/ admitted patients	214	Wuhan/China	CNS manifestation (25%): headache (13%), dizziness (13%), impaired consciousness (8%) acute cerebrovascular problem (3%), ataxia (0.5%), seizure (0.5%)
Li/2020	Retrospective/ admitted patients	221	Wuhan/China	IS (5%), CVST (0.5%), cerebral haemorrhage (0.5%)
Huang/2020	Prospective/ admitted	41	Wuhan/China	Headache (8%)
Yang/2020	Retrospective/ critical ill adult patients	52	Wuhan/China	Headache (6%)
Wang/2020	Retrospective/ admitted	138	Wuhan/China	Dizziness (9%), Headache (7%)
Chen/2020	Retrospective/ admitted	99	Wuhan/China	Confusion (9%), headache (8%)

Mao T et al. https://www.medrxiv.org/content/10.1101/2020.02.22.20026500v1/. Li Y et al. https://papers.ssrn.com/sol3/ papers.cfm?abstract\_id=3550025/,


Huanf C et al. Lancet 2000: 395; 497-506

Yang X, C et al. Lancet Res. Med 2000 inpress

Wang D et al. JAMA 2020 inpress

Chen N et al. Lancet 2000: 395; 507-513

#### https://www.dailymotion.com/video/x7samry



Pathophysiology

- Patients without epilepsy
  - Seizure
  - EEG
  - Treatment
  - Epilepsy
- Patients with epilepsy

#### https://www.dailymotion.com/video/x7samry MERS SARS CORONAVIRUS (COVID-19) Li Y, et al. Interirology 2016:59;163-169 Beijing, Chaina 0.5% 6/70 (9%) Saad M, et al. J Infcet Dis 2014:29;301-306 Riyadh, Saudi Arabia Mao L, et al. J Infcet Dis 2014:29;301-306 https://www.medrxiv.org/content/10.1101/2020.02.22.20026500v1/. Seizure **HCoV**


Colorado, USA

Dominguez SR, et al J Med Virol 2009;81:1597-1604



HCoV-OC43

#### COVID-19 and seizure



https://m.economictimes.com/thumb/msid-71344481,width-1200,height-900,resizemode-4,imgsize-523232/1.jpg


https://www.thailandmedical.news/uploads/editor/files/encephalitis.jpg

https://cardiff.imgix.net/\_\_data/assets/image/0011/25958/Fight-against-organ-failure-advances.jpg?w=873&h=491&fit=crop&q=60&auto=format

https://www.biovision.com/media/biovision/categories/metabolic-banner-09242019.jpg

https://prognoshealth.com/wp-content/uploads/2019/08/lung-cancer-image.jpeg

#### COVID-19 and seizure



Seizure

Neurotrophic pathogenic mechanism

Seizure: European Journal of Epilepsy 78 (2020) 109–112

Contents lists available at ScienceDirect

# EISEVIED

Seizure: European Journal of Epilepsy

journal homepage: www.elsevier.com/locate/seizure




Short communication

Focal status epilepticus as unique clinical feature of COVID-19: A case report



Catello Vollono<sup>a,\*,1</sup>, Eleonora Rollo<sup>b,1</sup>, Marina Romozzi<sup>b</sup>, Giovanni Frisullo<sup>c</sup>, Serenella Servidei<sup>a,b</sup>, Alberto Borghetti<sup>d</sup>, Paolo Calabresi<sup>b,c</sup>

- <sup>a</sup> Neurofisiopatologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- <sup>b</sup> Neurologia, Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy
- <sup>c</sup> Neurologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- <sup>d</sup> UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy



Pathophysiology

- Patients without epilepsy
  - Seizure
  - EEG
  - Treatment
  - Epilepsy
- Patients with epilepsy

#### EEG in COVID-19 patients in ICU

- EEG provide a readily available, safe, and effective means of evaluateing brain function
- Full 10-20 EEG placement with an ECG derivation remains the standard
- Using simplified montages may limit the risk of infection to EEG technologists
- Reduced montages with subdermal single-use EEG needle electrodes may be used in comatose COVID-19 patients.
- A prone (face-down) position is used for the treatment of acute respiratory distress syndrome to improve oxygenation.
- Prone positioning effects on the EEG in adults for periods of 16 hours per day are unknown
- Caution: Ventilator-triggered artifacts, head movements, water condensation within the tubing connected to the ventilator may produce artifacts that simulate intermittent polysharp-waves
- EEG pattern in ICU



#### The five key questions.

Status epilepticus versus metabolic/toxic encephalopathies.

Q1: Is it a confusional state or only a problem of vigilance?

Q2: Is there a fluctuation of symptoms or change in consciousness from somnolence to coma?

Q3: Is the EEG activity rhythmic or periodic?

Q4: Is the EEG activity dynamic, showing spatiotemporal evolution, or relatively monomorphic?

Q5: Is the EEG reactive to stimuli, wakefulness, sleep, arousal, or antiseizure drugs\*?

<sup>\*</sup> Only consider an IV benzodiazepine test positive if both EEG and consciousness normalize.

Pathophysiology

- Patients without epilepsy
  - Seizure
  - EEG
  - Treatment
  - Epilepsy
- Patients with epilepsy

## Management of seizures

- Diagnosis
- Evaluate causes
- First seizure:

#### Management of seizures

- Diagnosis
- Evaluate causes
- Drug factors: onset of action, drug interaction, respiratory failure, renal failure, liver failure

#### Duration of treatment

- New-onset seizures in these patients could be considered as acute symptomatic seizures.
- Patients with acute symptomatic seizures do not need long-term ASM therapy after the period of acute illness, unless a subsequent seizure occurs
- Patients with acute symptomatic seizures do not need long-term ASM therapy after the period of acute illness, unless a subsequent seizure occurs<sup>1,3</sup>
- Since the period from the onset of COVID-19 symptoms to death may range from 6 to 41 days<sup>2,3</sup>
- It is reasonable to continue the ASM for about 6 weeks and then tapper and discontinue the drug rapidly in 1–2 weeks.<sup>3</sup>

Pathophysiology

- Patients without epilepsy
  - Seizure
  - EEG
  - Treatment
  - Epilepsy

No Evidence

Patients with epilepsy

Pathophysiology

- Patients without epilepsy
  - Seizure
  - EEG
  - Treatment
  - Epilepsy
- Patients with epilepsy

#### Patients with seizures and COVID-19

- COVID-2 สามาถ precipitate or aggravate existing seizures ได้หรือไม่
- ผู้ป่วยโรคลมชักมีโอการที่จะติดเชื้อ COVID-2 ง่ายกว่าคนทั่วไปหรือไม่
- ยาที่ใช้รักษา COVID-19 ตัวใหนที่ควรเลือกใช้ในผู้ป่วยโรคลมชัก
- แพทย์ควรเปลี่ยนการดูแลผู้ป่วยโรคลมชักในสถาณการณ์ที่มีการระบาดของ
   COVID-19 อย่างไร

COVID-2 สามาถ precipitate or aggravate existing seizures ได้หรือไม่

- Seizures in severe/end-stage disease likely reflect COVID-19–related hypoxia, encephalopathy, or encephalitis than lowered seizure threshold in susceptible individuals with preexistent neurologic disease.
- Some may include new-onset seizures
- Individuals with epilepsy are not more likely to be infected by the virus, nor are they more likely to have severe COVID-19 manifestations because they have epilepsy

•

ผู้ป่วยโรคลมชักมีโอการที่จะติดเชื้อ COVID-2 ง่ายกว่าคนทั่วไปหรือไม่

- Individuals with epilepsy are not more likely to be infected by the virus, nor are they more likely to have severe COVID-19 manifestations because they have epilepsy
- May be concern: Autoimmune associated epilepsy, tuberous sclerosis, Dravet syndrome

#### ยาที่ใช้รักษา COVID-19 ตัวใหนที่ควรเลี่ยงในผู้ป่วยโรคลมชัก

- Some medications used to treat individuals with upper respiratory tract infections
- A number of medications are now being studied as possible treatments for COVID-19 to reduce viral load and/or severity of disease
  - Chloroquine and hydroxychloroquine, either alone or with azithromycin
  - Antiviral and immune therapies
    - carbamazepine and lopinavir/ritonavir or atazanavir combination
    - Phenytoin and lopinavir/ritonavir
    - Valproate/lamotrigine and lopinavir/ritonavir

แพทย์ควรเปลี่ยนการดูแลผู้ป่วยโรคลมชักในสถาณการณ์ที่มีการระบาดของ COVID-19 อย่างไร

- Reduce health. Care availability
- Attendance at medical facilities poses an additional risk of contracting the virus for individuals and their carers/families
- Clinicians should formulate approaches to reduce emergency department, clinic, and hospital visits
- People with epilepsy should have an emergency care plan
- The threshold to provide emergency rescue medication (e.g., benzodiazepines via buccal, nasal, or rectal routes or oral if they can be safely swallowed) may be lowered.
- Should be reassured that most tonic-clonic seizures last under 2–3 minutes and do not require emergency medical

แพทย์ควรเปลี่ยนการดูแลผู้ป่วยโรคลมชักในสถาณการณ์ที่มีการระบาดของ COVID-19 อย่างไร

- A regular supply of antiseizure medication should be ensured as well as access to repeat prescriptions and supplies
- Changes to treatment could be postponed
- Any initiated withdrawal/wean or down-titration of medication should be delayed or reversed unless there are strong reasons for doing otherwise.
- Key advice on lifestyle issues should be reinforced
- Telehealth
- For new presentations, care can be enhanced through careful history taking and home video where possible

แพทย์ควรเปลี่ยนการดูแลผู้ป่วยโรคลมชักในสถาณการณ์ที่มีการระบาดของ COVID-19 อย่างไร

- Diagnostic procedure can be delayed to a later date.
- A system to reduce direct exposure of health care professionals to people with epilepsy is advisable.